Skip Navigation
Megan McArdle

Megan McArdle - Megan McArdle is a senior editor for The Atlantic who writes about business and economics. She has worked at three start-ups, a consulting firm, an investment bank, a disaster recovery firm at Ground Zero, and The Economist. She is currently on leave.
More

Megan was born and raised on the Upper West Side of Manhattan, and yes, she does enjoy her lattes, as well as the occasional extra-dry skim-milk cappuccino. Her checkered work history includes three start-ups, four years as a technology project manager for a boutique consulting firm, a summer as an associate at an investment bank, and a year spent as sort of an executive copy girl for one of the disaster-recovery firms at Ground Zero � all before the age of 30.

While working at Ground Zero, Megan started Live From the WTC, a blog focused on economics, business, and cooking. She may or may not have been the first major economics blogger, depending on whether we are allowed to throw outlying variables such as Brad Delong out of the set. From there it was but a few steps down the slippery slope to freelance journalism. She has worked in various capacities for The Economist, where she wrote about economics and oversaw the founding of Free Exchange, the magazine's economics blog. She has also maintained her own blog, Asymmetrical Information, which moved to The Atlantic, along with its owner, in August 2007.

Megan holds a bachelor's degree in English literature from the University of Pennsylvania and an M.B.A. from the University of Chicago. After a lifetime as a New Yorker, she now resides in northwest Washington, D.C., where she is still trying to figure out what one does with an apartment larger than 400 square feet.

Think positive

By Megan McArdle
Oct 17 2007, 1:05 AM ET Comment

Derek Lowe dives into a problem that is far too poorly understood by most of the public: the problem of false positives.

The news of a possible diagnostic test for Alzheimer’s disease is very interesting, although there’s always room to wonder about the utility of a diagnosis of a disease for which there is little effective therapy. The sample size for this study is smaller than I’d like to see, but the protein markers that they’re finding seem pretty plausible, and I’m sure that many of them will turn out to have some association with the disease.

But let’s run some numbers. The test was 91% accurate when run on stored blood samples of people who were later checked for development of Alzheimer’s, which compared to the existing techniques is pretty good. Is it good enough for a diagnostic test, though? We’ll concentrate on the younger elderly, who would be most in the market for this test.The NIH estimates that about 5% of people from 65 to 74 have AD. According to the Census Bureau (pdf), we had 17.3 million people between those ages in 2000, and that’s expected to grow to almost 38 million in 2030. Let’s call it 20 million as a nice round number.

What if all 20 million had been tested with this new method? We’ll break that down into the two groups – the 1 million who are really going to get the disease and the 19 million who aren’t. When that latter group gets their results back, 17,290,000 people are going to be told, correctly, that they don’t seem to be on track to get Alzheimer’s. Unfortunately, because of that 91% accuracy rate, 1,710,000 people are going to be told, incorrectly, that they are. You can guess what this will do for their peace of mind. Note, also, that almost twice as many people have just been wrongly told that they’re getting Alzheimer’s than the total number of people who really will.


People look at tests with small error rates--a false positive rate of, say, .5%, and conclude that if they test positive, that means it's overwhelmingly likely that they have the disease. But this is true only for conditions that are relatively frequent. Take a test for a disease that has a false positive rate of 5%, and a disease prevalence of 1 in 1000--lupus, say. If you test positive in a random assay, what are the odds that you actually have the disease?

Most people--even, apparently, a shocking number of doctors--would say that the odds are 95%. But this is all wrong. If you test 1,000 people for lupus, 1 of them will correctly test positive for lupus--and 50 of them will falsely test positive. The chances are only 1 in 51, less than 2%, that you actually have the disease.

These are in fact the actual numbers for anti-nuclear antibody tests and systemic lupus, at least as relayed to me by my immunologist after I got a borderline positive result on a screen. These suggest that no one should ever do a random ANA; the information it gives is garbage, particularly since they don't treat lupus until you manifest symptoms. Yet lots of doctors, including mine, do.

Presented by

More at The Atlantic

David Cameron, Europe's Latest Scapegoat David Cameron, Europe's Latest Scapegoat
'Men in Black 3': A Could-See 'Men in Black 3': A Could-See Film
It's Not Just Porn: Why Ultra-Orthodox Jews Fear the Internet Why America's Ultra-Orthodox Jews Fear the Internet
How Google Can Beat Facebook Without Google Plus How Google Can Win the Social Media War
Buying a Piece of America: Why Chinese Shoppers Love U.S. Brands Why Chinese Shoppers Love American Brands

Join the Discussion

After you comment, click Post. If you’re not already logged in you will be asked to log in or register.
blog comments powered by Disqus

Just In

View All Correspondents

The Biggest Story in Photos

The American West, 150 Years Ago

May 24, 2012

Subscribe Now

SAVE 59%! 10 issues JUST $2.45 PER COPY

Facebook

Newsletters

Sign up to receive our free newsletters

(sample)

(sample)

(sample)

(sample)

(sample)

(sample)

Megan McArdle
from the Magazine

Why You Can’t Get a Taxi

And how an upstart company may change that

Europe’s Real Crisis

The Continent’s problems are as much demographic as financial. They won’t go away soon.

Why Companies Fail

GM’s stock price has sunk by a third since its IPO. Why is corporate turnaround so difficult…